+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Keytruda"

Keytruda Global Market Report 2024 - Product Thumbnail Image

Keytruda Global Market Report 2024

  • Report
  • August 2024
  • 175 Pages
  • Global
From
KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
From
Melanoma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Melanoma Therapeutics - Global Strategic Business Report

  • Report
  • February 2025
  • 162 Pages
  • Global
From
Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Metastatic Uveal Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Uveal Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
From
From
From
Loading Indicator

Keytruda is a type of skin cancer drug used to treat melanoma, a type of skin cancer. It is a type of immunotherapy, which works by helping the body’s immune system recognize and attack cancer cells. Keytruda is a monoclonal antibody, which means it is designed to target a specific protein on the surface of cancer cells. It is approved for use in adults and children with advanced melanoma, and is also being studied for use in other types of cancer. Keytruda is one of several skin cancer drugs on the market. Other drugs used to treat melanoma include Yervoy, Opdivo, and Tecentriq. These drugs are all immunotherapies, and work in different ways to help the body fight cancer. Companies in the Keytruda market include Merck, which manufactures the drug, as well as Bristol-Myers Squibb, Roche, and AstraZeneca. These companies are all involved in the research, development, and marketing of Keytruda and other skin cancer drugs. Show Less Read more